Provention Bio, Inc. (PRVB): Price and Financial Metrics
PRVB Price/Volume Stats
| Current price | $24.98 | 52-week high | $25.00 |
| Prev. close | $24.23 | 52-week low | $3.18 |
| Day low | $24.98 | Volume | 9,124,100 |
| Day high | $25.00 | Avg. volume | 2,277,701 |
| 50-day MA | $18.51 | Dividend yield | N/A |
| 200-day MA | $9.84 | Market Cap | 2.37B |
PRVB Stock Price Chart Interactive Chart >
Provention Bio, Inc. (PRVB) Company Bio
Provention Bio, Inc. operates as a biopharmaceutical company. The Company focuses on development of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Provention Bio serves patients in the State of New Jersey.
Latest PRVB News From Around the Web
Below are the latest news stories about PROVENTION BIO INC that investors may wish to consider to help them evaluate PRVB as an investment opportunity.
Sanofi/Provention: innovative diabetes drug is a good fitUS diabetes drugmaker Provention Bio is a case in point. Sanofi has bought it for $2.9bn in cash, more than three times its undisturbed price, in a deal that closed last week. The deal is a good fit for Sanofi, even though boss Paul Hudson pulled back from diabetes research in 2019. |
Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit... |
Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineProvention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More InformationSanofi SA (NASDAQ: SNY) withdrew and refiled the Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act “following informal discussions with the staff of the” Federal Trade Commission (FTC) regarding the acquisition of Provention Bio Inc (NASDAQ: PRVB). Sanofi agreed to acquire Provention Bio at $25 per share in a deal valued at $2.9 billion. The agency, it added, needed more time to look at the deal and “information recently provided to them,” Sanofi said |
Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
PRVB Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 286.09% |
| 5-year | 146.59% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 88.08% |
| 2021 | -66.82% |
| 2020 | 13.69% |
| 2019 | 741.81% |
Loading social stream, please wait...